Rebirth of the God-level Xueba

Arnold finished the phone call and returned happily. He saw that Yang Rui had been with a table of pharmaceutical company representatives and drank a sheaf of beer after pushing a glass for a change.

Arnold’s eye sockets turned red in an instant, as if a man went out to buy a spring onion, and found three more used sets in the kitchen when he came back, and as if a man rushed out to buy a set, and he came back and found that there were six more broken green onions in the bedroom. Bitter gourd.

Arnold's heart is bitter like a broken organic bitter gourd-my life, my struggle, my goal, is not to do this kind of thing!

"Arnold is here. Let's have a drink together." Yang Rui invited Arnold to the table as if nothing was wrong, even calling him a nickname.

In the eyes of a group of colleagues, Arnold sat down on the table coldly and said, "Yang Rui, I think it is true that you promised Zelican the right of first refusal."

"Of course it is true. Before signing a contract with any company, I will tell Zelican and give you a short quote time." Yang Rui put down his beer glass and said.

Priority was originally such a thing. Arnold had nothing to say and said disappointedly: "I thought you would give us a chance to talk first and talk privately."

"If it's moved by emotion, I don't want it." Yang Rui knows what Arnold thinks. The relationship between the two parties has become inseparable to this day. If the British intercede, if the relationship is used to speak, Yang Rui is really not. Good to refuse.

"Zelican's conditions will definitely satisfy you." Arnold wanted to do additional questions too much, especially when his answer to the basic questions was not particularly good.

Yang Rui said: "I know that Zelecom will provide excellent conditions, and it will be enough to make up for the efforts of Huarui Laboratory, perhaps enough to make up for many times that Huarui Laboratory has paid, but I have to be responsible for Huarui, for including me The researchers inside are responsible, and we want the best conditions."

Yang Rui looked around and said: "Deferiprone is my first achievement in the field of pharmacology, and it is also the first achievement of Huarui Lab. I don't know if this is ability or good luck, or just a flash of light. , I have to fight for what I can, this is my duty, right?"

"I admit that what you said is very reasonable. You want to redeem an insurance for Huarui, so that it can operate for many years. I can understand it, but I want to say that Zelecom can be your insurance company. The good relationship with Zelecom can also guarantee the long-term operation of Huarui Laboratory." Arnold has a lot to say, but he chose this statement because it is a condition that only Zeleca can propose.

No matter how large other companies are, they would not dare to make such a guarantee without the basis for cooperation with Yang Rui.

Yang Rui picked up the beer glass and took a sip, letting the wine rotate in his mouth, feeling the bitter taste.

"Yang Rui, the resources owned by Zelecom are world-class. What we can provide to you is more likely to be the first in the world. I can guarantee that even if, I mean, even if the Huarui laboratory will be in the next seven years Here, there is no output, and I also guarantee that you are Zelican's partners and enjoy the treatment of a first-class laboratory." Arnold once again proposed a condition that other companies cannot offer.

In fact, he still has many conditions to say, such as price, such as authorization, but he does not want to get into a price war. The relationship between the two sides is Arnold's biggest bargaining chip, and the scale of Zeleca is his biggest reliance.

I have to say that Yang Rui is a little moved.

The seven-year partnership and the treatment of first-class laboratories are really nothing to say, and Yang Rui believes that Arnold can fulfill his promise.

The development of new drugs, especially the development of original drugs, is extremely difficult, and it is getting more and more difficult. In the 1950s and 1960s, pharmaceutical companies were keen to develop antibiotics, and almost all the bacteria in the soil were searched. Schools such as Harvard also launched a campaign to ask everyone to mail the soil near their homes. At that time, antibiotics Appearing at a rate of several kinds per month, it is not difficult for larger pharmaceutical companies to develop more than a dozen new drugs a year, but by the 1970s, with the development of technology and strict drug supervision, single-digit new drugs have become the norm. . As far as Yang Rui knows, after 2010, the time expectation of large pharmaceutical companies to develop new drugs has extended to ten years-ten years can develop a new drug, even if it is fast.

Against this background, the patience of pharmaceutical companies is actually very good, not to mention young and experienced scholars like Yang Rui, who is a slightly famous professor at a prestigious university. He has just stepped into this field, and the patience of pharmaceutical companies can last for two to three. Years, even three or four years.

Seven years is beyond the patience of a normal company, but with the support of Arnold and the support of world-class results, Yang Rui is indeed qualified to receive such a promise.

However, Yang Rui didn't want such a promise in his heart.

If Yang Rui is an ordinary scholar, the inseparable relationship should be welcomed. Large multinational pharmaceutical companies are the best partners in the biological and pharmaceutical fields. Of course, they will still bully people and shoppers, but that does not mean that Small pharmaceutical companies will not do this. The only difference is that large pharmaceutical companies have better food, longer patience, more funding, and stronger funding and execution capabilities.

It is a pity that Yang Rui is not an ordinary researcher. There are too many things in his head.

At the current rate, the development of a new original drug in two months may seem to others to be a coincidence or even a fantasy, but for Yang Rui, this is indeed a work that can be replicated.

Yang Rui can do what those generic drug companies do after the original drug information is made public.

The only problem is that the complexity of original drugs far exceeds that of generic drugs.

The market value of Zelekang is nearly 100 billion, and its annual sales are over 10 billion. But when it comes to new drugs, it is not bad if there are three each year, and it may be a new drug composed of different compounds with the same target. Just like Yang Rui's deferiprone left seven active substances in the end, if all the seven active substances passed the clinical trials, it would be equivalent to seven new drugs.

This is also the reason why deferiprone is valued by many companies. The sales of deferiprone itself may not be high, but it has a great chance of passing clinical trials and going public. This is enough for companies to focus on.

Yang Rui's future work will only attract more and more attention, but Zelican's scale cannot be expanded rashly.

In fact, pharmaceutical companies often encounter similar situations. For example, there were too many compounds synthesized in the year, or there were too many targets found in the year, what should be done? It's so easy to do. I'll do it next year.

From the company's point of view, this behavior is called technology reserve.

When Wall Street evaluates pharmaceutical companies, drug storage is also a very important part. Moreover, not only the synthetic compounds can be stored, how many phase three clinical trials, how many phase two clinical trials, and how many drugs passed in animal experiments can also be used as a reference for storage and evaluation.

At Yang Rui's speed, he does not want his invention to be reserved by the company, even if the research after the storage is more profitable, Yang Rui is not happy.

He needs a lot of money, even a huge amount of money, but his goal has never been simply to make money.

Yang Rui is destined to look for partners other than Zelecom.

If it had agreed to Arnold's promise, or waited for Deferrone to go on the market, Zelecao would not let Yang Rui out easily.

At that time, Zelecom will definitely strengthen its relationship with Yang Rui, which may result in a lot of short-term benefits, but that is not what Yang Rui wants.

Arnold must not be able to guess, it is precisely because of his promise that Yang Rui made up his mind.

"I believe what you said, but Hua Rui wants to rely on himself." Yang Rui clearly rejected Arnold, then opened a bottle of beer, filled the glass in front of Arnold, and gently touched it with the beer bottle, and said: "King each Do your part."

"Respect each to do his duty." Yang Rui raised his glass to the others again.

"Respect each one's duty!" Everyone toasted one after another.

Raymond of Greenstone Point even drank a large glass of beer. These business elites from developed countries are indeed proud of their "duty". If they are not dedicated, who would sit on the streets of a foreign country, eating the offal of cattle, sheep and pigs, and smelling the rot of stinky tofu.

"How does it taste?" Yang Rui chewed on the stew, pushed his belly into the middle of the table, and said, "My two are my favorite Beijing snacks. You are welcome."

The elites grind their teeth vigorously with a broken belly.

After a while, the Japanese took the lead in raising their heads with tears in their eyes and said: "Very delicious, Chinese food is extensive and profound, and it's so delicious."

Raymond also raised his thumb, his eyes gleaming, and choked with sobs: "Chinese food is great."

"Just like it, just like it." Yang Rui smiled and put down his chopsticks.

Others hurriedly dropped their chopsticks, the Italian took a deep breath, then suddenly pinched his nose, his eyes widened.

"Smelly tofu is not very good, but it is delicious." Yang Rui explained with a smile, and added: "China, like other countries in the world, has many characteristics of its own, and Chinese people also have many habits of their own. But the whole world has similar problems, the biggest trouble, in today's world, I think it is probably disease."

Yang Rui pointed to himself and then to the Americans, and said with a smile: "The Cold War should not be a hot issue anymore."

"Maybe Reagan cares, I don't care." Raymond smiled.

"I don't care either, and what I care about is whether Deferiprone can be successfully listed and listed as soon as possible." Seeing that Yang Rui finally got to the point, everyone else straightened their waists.

"Do you want to have a small auction?" the Italian asked.

"No, no, what I want now is not competition, but cooperation." Yang Rui shook his head again and again: "Just what I said, I hope that Deferrone can be listed smoothly, and it will be listed as soon as possible, so I asked to buy it. Companies with iron ketones must be strong and have a strong ability to market drugs."

The faces of representatives of several companies were unsightly.

A strong drug listing capability is not to say. If there is an evaluation standard, a company that has a new drug listing every year is a company that has a strong drug listing capability, just like a film company that produces new movies every year. It can be called a powerful film production company.

And there will never be more companies that can do this.

More than half of the companies here are not considered powerful.

"Please stay calm." Yang Rui's smile was contagious. He raised the cup again and said: "I know that different pharmaceutical companies have different business models. For example, some companies are good at drug development..."

He looked at the British and the Norwegians.

"Some companies are good at marketing." Yang Rui looked at American Raymond.

"Some companies are good at developing new indications for existing drugs." Yang Rui looked at the Germans and Japanese.

"Some companies are good at..." Yang Rui looked at the rest of the Italians who were eager to try, and said: "Good at some other jobs..."

"But anyway." Yang Ruimeng clapped his hands and smiled: "The listing of new drugs is a big project. I respect your business methods, but I will choose the company or combination of companies with the most listing capabilities."

Except for the Italians who are still bewildering what "other" is, other companies have come to understand.

Raymond asked: "Do you want you to join forces and buy a patent for deferiprone?"

"It is your freedom to unite or not to unite~www.NovelMTL.com~ But for companies that are more capable of going public, I am willing to transfer some of the benefits." Yang Rui paused, then said: "We can bet

At this moment, representatives of various companies came to be interested.

The pharmaceutical industry is one of the industries most closely linked to finance. Those merger agreements that cost tens of millions or even billions of dollars require investment banks to participate. The development of new medicines that cost hundreds of millions or even billions of dollars requires hedging by the insurance industry. The tens of billions of sales revenue requires the intervention of commercial banks.

The gambling agreement is the most common contract in the development of new drugs.

It can even be said that gambling is an inevitable contract in the development of new drugs. In the process of new drug development with such a low probability, scientists and laboratories are gambling, laboratories are gambling with biotechnology companies, and biotechnology companies are gambling with pharmaceutical companies. Pharmaceutical companies can bet against Wall Street. Layers of betting agreements can help professional companies lock in profits to the greatest extent, just like commodity circulation companies use futures trading to lock in risks.

Of course, the reason why people like gambling agreements is often not because of locking in profits. More people simply like gambling, just like many commodity circulation companies silently modify futures value-preserving transactions into futures value-preserving and increasing transactions.

For pharmaceutical companies that are in a dominant position in the gambling agreement, they can choose to sell higher-risk gambling items to Wall Street, while leaving the lower-risk and higher-profit gambling items to themselves.

Yang Rui's request is equivalent to guaranteeing the profit of the pharmaceutical company.

Everyone likes to make a profit without losing money.